Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy

Neurology

Volumn 84, Issue 19, 2015, Pages 1972-1980

  Gidal, Barry E ^a   Laurenza, Antonio ^b   Hussein, Ziad ^b,c   Yang, Haichen ^a   Fain, Randi ^b   Edelstein, Jacob ^d   Kumar, Dinesh ^b   Ferry, Jim ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b EISAI INC   (United States)

^c EISAI CO LTD   (Japan)

^d Sui Generis Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450 3A4; PERAMPANEL; PHENOBARBITAL; PLACEBO; TOPIRAMATE; CYTOCHROME P450 3A INDUCER; DRUG COMBINATION; PYRIDONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CHILD; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INDUCTION; EPILEPSY; FALLING; FATIGUE; FREQUENCY; HUMAN; IRRITABILITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; FEMALE; INTERNATIONAL COOPERATION; MALE; MENTAL DISORDERS; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; CYTOCHROME P-450 CYP3A INDUCERS; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; EPILEPSY; FATIGUE; FEMALE; HUMANS; INTERNATIONALITY; MALE; MENTAL DISORDERS; PYRIDONES; TREATMENT OUTCOME;

EID: 84929208989     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001558     Document Type: Article

References (23)

1. French JA. Refractory epilepsy: clinical overview. Epilepsia 2007;48:3-7.
2. Perucca E, French JA, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007;6:793-804.
3. Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;78:1548-1554.
4. Rektor I. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistance partial-onset seizures. Expert Opin Pharmacother 2013;14:225-235.
5. Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl 2013;197:19-24.
6. Fycompa [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; 2014.
7. Fycompa [summary of product characteristics]. Hatfield, UK: Eisai Europe Limited; 2012.
8. Fycompa [product monograph]. Mississauga, ON: Eisai Limited; 2013.
9. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589-596.
10. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partialonset seizures: results of randomized global phase III study 305. Epilepsia 2012;54:117-125.
11. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-1415.
12. Franco V, Crema F, Iudice A, Zaccarad G, Grillo E. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res 2013;70:35-40.
13. Gidal BE, Ferry J, Majid O, Hussein Z. Concentrationeffect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia 2013;54: 1490-1497.
14. Hussein Z, Critchley D, Ferry J, Laurenza A. Population pharmacokinetics of perampanel, a selective, noncompetitive AMPA receptor antagonist, in patients with refractory partial-onset seizures participating in a randomized, double-blind, placebo-controlled phase III study. Poster presented at the 29th International Epilepsy Congress; August 28-September 1, 2011; Rome.
15. Hussein Z, Ferry J, Krauss GL, Squillacote D, Laurenza A. Demographic factors and concomitant antiepileptic drugs have no effect on the pharmacodynamics of perampanel. Poster presented at the 64th Annual Meeting of the American Academy of Neurology; April 21-28, 2012; New Orleans.
16. Hsu WW, Sing CW, He Y, Worsley AJ, Wong ICK, Chan EW. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partialonset epilepsy CNS Drugs 2013;27:817-827.
17. Laurenza A, Gidal B, Hussein Z, et al. Evaluation of efficacy and safety of perampanel in the presence of concomitant CYP3A4-inducing AEDs: analyses from the perampanel phase 3 clinical trials. Poster presented at the 66th American Epilepsy Society Annual Meeting; November 30-December 4, 2012; San Diego.
18. Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizure: a pooled analysis of three phase III studies. Epilepsia 2013;54:1481-1489.
19. St. Louis EK. Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr Neuropharmacol 2009;7:96-105.
20. Gidal BE, French JA, Grossman P, Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009;72:419-425.
21. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis. Epilepsia 2012;53:512-520.
22. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 2013;54:11-27.
23. Kramer LD, Satlin A, Krauss GL, et al. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia 2014;55:423-431.